{"denoms":[{"counts":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"222"}],"units":"Participants"}],"groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"BG000","title":"Ruxolitinib"},{"description":"Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.","id":"BG001","title":"Best Available Therapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.48","value":"61.1"},{"groupId":"BG001","spread":"10.25","value":"59.1"},{"groupId":"BG002","spread":"10.39","value":"60.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"103"}]}],"title":"< 60 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"119"}]}],"title":"≥ 60 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"76"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"146"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"96"},{"groupId":"BG002","value":"194"}]}],"title":"White/Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Black/African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"27"}]}],"title":"Asian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.09","value":"76.6"},{"groupId":"BG001","spread":"17.34","value":"79.0"},{"groupId":"BG002","spread":"15.83","value":"77.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.44","value":"172.2"},{"groupId":"BG001","spread":"9.79","value":"173.3"},{"groupId":"BG002","spread":"9.14","value":"172.8"}]}]}],"description":"Height was missing at study entry for one participant in the ruxolitinib arm.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.82","value":"25.8"},{"groupId":"BG001","spread":"4.24","value":"26.1"},{"groupId":"BG002","spread":"4.03","value":"25.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Mass Index (BMI)","unitOfMeasure":"kg/m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"153"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"65"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}],"title":"2"}],"description":"Eastern Cooperative Oncology Group (ECOG) - ECOG Status: 0=Fully active, able to carry on all pre-disease performance without restriction; 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; 2=Ambulatory and capable of all selfcare but unable to carry out any work activities up and about more than 50% of waking hours","paramType":"NUMBER","title":"ECOG performance status","unitOfMeasure":"participants"}],"populationDescription":"All enrolled participants, regardless treated or not."}